Don't Judge GE HealthCare Technologies on Technicals Alone - Check Its Fundamentals!

Large-cap Technology company GE HealthCare Technologies has moved 0.3% so far today on a volume of 617,926, compared to its average of 2,838,507. In contrast, the S&P 500 index moved -0.0%.

GE HealthCare Technologies trades -17.49% away from its average analyst target price of $82.54 per share. The 12 analysts following the stock have set target prices ranging from $66.0 to $97.0, and on average have given GE HealthCare Technologies a rating of buy.

Anyone interested in buying GEHC should be aware of the facts below:

  • Based on its trailing earnings per share of 3.37, GE HealthCare Technologies has a trailing 12 month Price to Earnings (P/E) ratio of 20.2 while the S&P 500 average is None

  • GEHC has a forward P/E ratio of 16.1 based on its forward 12 month price to earnings (EPS) of $4.22 per share

  • Its Price to Book (P/B) ratio is 4.35 compared to its sector average of None

  • GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.

  • Based in Chicago, the company has 50,000 full time employees and a market cap of $31.0 Billion. GE HealthCare Technologies currently returns an annual dividend yield of 0.1%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.